T10009 |
JAK3-IN-7 |
JAK3-IN-7 is an effective and selective JAK3 inhibitor (IC50 <0.01 μM) extracted from patent WO2011013785A1. |
T10424 |
AZ-3 |
AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM). |
T10431 |
AZD4205 |
AZD4205 is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM). |
T11690 |
ITK inhibitor 2 |
ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM. |
T11708 |
JAK2-IN-4 |
JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively. |
T11709 |
JAK3 covalent inhibitor-1 |
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. |
T11710 |
JAK-IN-5 |
JAK-IN-5 is an inhibitor of JAK. |
T11711 |
Jaspamycin |
Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity. Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to ...
|
T11713 |
JBJ-02-112-05 |
JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 15 nM for EGFRL858R/T790M. |
T11714 |
JBJ-04-125-02 |
JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities. JBJ-04-125-02 is a potent, mut...
|
T11721 |
JDTic |
JDTic has a very long duration of action, with effects in animals seen for up to several weeks after administration of a single dose, although its binding to th...
|
T11721L |
JDTic dihydrochloride |
JDTic is a potent antagonist of kappa-opioid receptors (KOR), blocking the κ-agonist U50, 488-induced antinociception. |
T12091 |
MM-589 |
MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction. |
T12091L |
MM-589 TFA |
MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction. |
T12427 |
PF-06700841 (P-Tosylate) |
PF-06700841 P-Tosylate is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively). |
T12549 |
JAK-IN-11 |
JAK-IN-11 is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment. |
T14687 |
BMS-986165 |
BMS-986165 inhibits IL-12/23 and type I IFN pathways. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoi...
|
T15037 |
Momelotinib Mesylate |
Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3. |
T15038 |
Momelotinib sulfate |
Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3. |
T15096 |
Delgocitinib |
Delgocitinib is a novel and specific inhibitor of JAK (IC50s: 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2). |
T15606 |
JAK1-IN-4 |
JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM). JAK1-IN-4 is an effective and selective JAK1 inhibitor (IC50s: 85 nM, 12.8 μM and ...
|
T16995 |
TAS05567 |
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3,...
|
T1829 |
(R)-RuxolitinibHOT |
Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50: 3.3/2.8 nM) and is relatively less selective for JAK3 (IC50: 322 nM). |
T1849 |
Momelotinib |
Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 competes with...
|
T1929 |
Filgotinib |
GLPG0634(filgotinib) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively. |
T1985 |
WHI-P154 |
WHI-P154 is a potent JAK3 inhibitor. |
T1995 |
FedratinibHOT |
Fedratinib (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3. |
T2012 |
Oclacitinib |
Oclacitinib(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 nM). |
T2035 |
WHI-P258 |
WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3. This compound binds JAK3 weakly and may be used as a JAK-binding negative control in the development of ne...
|
T2045 |
WHI-P131 |
Janex-1 is a cell-permeable, reversible, effective, ATP-competitive, and selective inhibitor of JAK3 (IC50: 78 μM); little inhibitory against JAK1/2, or Zap/S...
|
T2156 |
WP1066 |
WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 h...
|
T2360 |
Baricitinib Phosphate |
Baricitinib phosphate is a selective orally bioavailable JAK1/JAK2 inhibitor. |
T2398 |
Tofacitinib CitrateHOT |
Tofacitinib citrate is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM). |
T2485 |
Baricitinib |
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activit...
|
T2487 |
Cerdulatinib |
Cerdulatinib is an novel oral dual Syk/JAK inhibitor. |
T2600 |
AG-490 |
AG-490 (Tyrphostin AG 490) is an inhibitor of EGFR (IC50: 0.1 μM). It is 135-fold more selective for EGFR than ErbB2, also inhibits JAK2 with no effect to Lyn,...
|
T2636 |
Decernotinib |
Decernotinib(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays. |
T2638 |
Gandotinib |
LY2784544(Gandotinib) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM). The selectivity is higher 8- and 20-fold than JAK1 and JAK3...
|
T2709 |
TAK901 |
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others...
|
T2853 |
Curcumol |
Curcumol, a pure monomer isolated extracted from Rhizoma Curcumaeis, has antitumor activities. |
T2S1040 |
Jolkinolide B |
Jolkinolide B has potent anti-inflammatory, and antitumor activities, it is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part,...
|
T2S1975 |
Ponicidin |
Ponicidin has anti-leukemia, immunoregulatory and anti-inflammatory functions, it also has anti-viral function especially in the upper respiratory tract infecti...
|
T3024 |
Avitinib |
Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with poten...
|
T3042 |
JAK2 Inhibitor V |
NSC 42834(JAK2 Inhibitor V, Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner. |
T3043 |
Ruxolitinib (INCB-18424) phosphate |
Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivi...
|
T3065 |
TG101209 |
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM. |
T3068 |
AT9283 |
AT9283 is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I). |
T3069 |
AZD1480 |
AZD1480 is a novel ATP-competitive JAK2 inhibitor (IC50: 0.26 nM), selectivity act against Tyk2 and JAK3, and to a smaller extent against JAK1. AZD1480 has been...
|
T3072 |
XL019 |
XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1. |
T3076 |
GLPG0634 analogue |
GLPG0634 (analog) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively. |
T3080 |
Pyridone 6 |
Pyridone 6(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying sign...
|
T3201 |
WDR5-0103 |
WDR5-0103 is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM). |
T3398 |
Icaritin |
Icaritin has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase arrest and apopt...
|
T3620 |
Solcitinib |
Solcitinib (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus...
|
T3673 |
Mollugin |
Mollugin may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for...
|
T3998 |
Itacitinib |
Itacitinib is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity. |
T4209 |
TAK-659 hydrochloride |
TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent...
|
T4210 |
SAR-20347 |
SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM). |
T4227 |
SB1317 hydrochloride (1204918-72-8(free base)) |
SB1317 is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM). |
T4476 |
AS1517499 |
AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM |
T4657 |
WHI-P97 |
WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipox...
|
T4672 |
Brevilin A |
Brevilin A is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperact...
|
T5049 |
NVP-BSK805 |
NVP-BSK805 is an ATP-competitive JAK2 inhibitor. |
T5091 |
FM381 |
FM381 is a potent covalent reversible inhibitor of JAK3. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK...
|
T5140 |
WDR5-0103 hydrochloride[890190-22-4(free base)] |
WDR5-0103 is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM). |
T5382 |
PF-06651600 |
PF-06651600 is a potent JAK3-selective inhibitor (IC50: 33.1 nM). |
T5492 |
JAK3-IN-6 |
JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM |
T5S0993 |
Kurarinone |
Kurarinone exhibits anti-tumor, estrogenic, and anti-inflammatory activities, it also shows strong inhibitory effect on immune responses. Kurarinone may amelior...
|
T5S1467 |
Cucurbitacin E |
Cucurbitacin E has prevention of neurodegeneration, it has potent anti-proliferative, antineoplastic, anti-inflammatory and analgesic actions, it also exhibits ...
|
T6020 |
Pacritinib |
Pacritinib (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays). |
T6104 |
Cerdulatinib hydrochloride |
Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and ...
|
T6124 |
Mubritinib |
Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM. |
T6145 |
ZM 39923 HCl |
ZM 39923 HCl is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutamina...
|
T6156 |
S-Ruxolitinib |
Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor. |
T6266 |
PP2 |
PP2 is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2. |
T6309 |
AZ 960 |
AZ 960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM). |
T6321 |
Tofacitinib |
Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis. |
T6790 |
BMS-911543 |
BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2. |
T6838 |
FLLL32 |
FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM). |
T6914 |
Oclacitinib maleate |
<p>Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, w...
|
T6916 |
OICR-9429 |
OICR-9429 is a potent antagonist of the interaction that WDR5 effect with peptide regions of MLL and Histone 3. It reduces the viability of acute myeloid leukem...
|
T6920 |
ON123300 |
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11nM). |
T7499 |
TAK-779 |
TAK-779 is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3). |
T7503 |
Upadacitinib |
Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 4...
|
T8546 |
BD750 |
BD750 is a JAK3/STAT5 inhibitor and an effective immunosuppressant that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.1 μM and...
|
TJS1779 |
Protosappanin A |
Protosappanin A has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB infl...
|
TMA1743 |
Ergosterol peroxide |
Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Fo...
|
TN1059 |
Ganoderic acid B |
Ganoderic acid B is a chemical marker in quality control of G. lucidum and related products. Ganoderic acid B-containing herbs has potential influence towards t...
|
TN2002 |
Obovatol |
Obovatol has antioxidant, neuroprotective, antiinflammatory, antithrombotic and antitumour effects, it is a potent NF-κB inhibitors for Alzheimer's disease tre...
|
TN2511 |
1,6-O,O-Diacetylbritannilactone |
1,6-O,O-Diacetylbritannilactone(OODBL) has anti-inflammatory activity, it has a potential therapeutic efficacy on inflammatory diseases especially allergic airw...
|
TN2775 |
2-Methoxystypandrone |
2-Methoxystypandrone displays an immunomodulatory effect in a cellular model, it blocks inflammatory responses by impairing NF-κB signaling to limit the infl...
|
TN3364 |
Agrimonolide |
Agrimonolide is a potential α1 adrenergic receptor antagonist, it exerts anti-inflammatory activity, at least in part, via suppressing LPS-induced activation o...
|
TN3541 |
Broussonin E |
Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathw...
|
TN4774 |
Physalin A |
Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling, it inhibits androgen-independent prostate can...
|
TQ0010 |
PF-06700841 |
PF-06700841 is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). It also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM). |
TQ0037 |
Abrocitinib |
Abrocitinib (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2). |
TQ0061 |
CHZ868 |
CHZ868 is a type II JAK2 inhibitor (IC50: 0.17 μM in EPOR JAK2 WT Ba/F3 cell). |
TQ0196 |
Cucurbitacin I |
Cucurbitacin I, a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity. |